← Back to Search

Cell Therapy

B2 for Heart Failure

Phase 1 & 2
Waitlist Available
Led By Emerson C. Perin, MD, PhD
Research Sponsored by Angioblast Systems
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group

Summary

Primary Objective The primary objective of this study is to evaluate the safety and feasibility of transendocardial injection using the Cordis Biosense NogaStarTM Mapping Catheter with the Biosense MyostarTM Left Ventricular Injection Catheter of 25 M, 75 M, and 150 M allogeneic mesenchymal precursor cells (MPCs) in subjects with AMI. SecondaryObjective The secondary objectives are to explore functional efficacy for subsequent study design, as well as late-term dose related tolerance, by: * Evaluating the effect of allogeneic MPCs on exploratory efficacy endpoints related to cardiac function on Days 90, 180, and 1 year * Evaluating the change from baseline in the Medical Outcome Study Short Form (SF-36), Kansas City Cardiomyopathy Questionnaire, Seattle Angina Questionnaire, and the New York Heart Association Classification at 30 days, 3 and 6 months, and 1, 2, and 3 years * Evaluating follow-up safety through Day 360 * Providing preliminary data to support dose selection for future studies

Eligible Conditions
  • Heart Failure
  • Heart Attack

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

6Treatment groups
Experimental Treatment
Group I: C2Experimental Treatment1 Intervention
2 subjects randomized to receive standard-of-care treatment with NOGA® mapping and staged injections.
Group II: C1Experimental Treatment1 Intervention
5 subjects randomized to receive 150 M allogeneic MPCs by transendocardial injection
Group III: B2Experimental Treatment1 Intervention
3 subjects randomized to receive standard-of-care treatment with NOGA® mapping and staged injections.
Group IV: B1Experimental Treatment1 Intervention
5 subjects randomized to receive 75 M allogeneic MPCs by transendocardial injection
Group V: A2Experimental Treatment1 Intervention
5 subjects randomized to receive standard-of-care treatment with NOGA® mapping and staged injections.
Group VI: A1Experimental Treatment1 Intervention
5 subjects randomized to receive 25 M allogeneic MPCs by transendocardial injection
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Allogeneic Mesenchymal Precursor Cells (MPCs)
2014
Completed Phase 3
~570

Find a Location

Who is running the clinical trial?

Angioblast SystemsLead Sponsor
1 Previous Clinical Trials
10 Total Patients Enrolled
1 Trials studying Heart Failure
10 Patients Enrolled for Heart Failure
Emerson C. Perin, MD, PhDPrincipal InvestigatorTexas Heart Institute/St. Luke's Hospital
1 Previous Clinical Trials
3 Total Patients Enrolled
~1 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top